On February 16, 2022, FDA revealed a compounding possibility inform describing the likely challenges connected with at-home use of compounded ketamine nasal spray and several other adverse celebration studies. The February 2022 compounding hazard notify also offered information about Spravato, which is topic to a Hazard Evaluation and Mitigation Ta